Management of locally advanced prostate cancer

Asian Journal of Andrology

Volumn 11, Issue 1, 2009, Pages 81-87

  Payne, Heather ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; ANTIANDROGEN;

ADJUVANT THERAPY; ADVANCED CANCER; BONE DENSITY; BRACHYTHERAPY; BREAST SWELLING; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GYNECOMASTIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIBIDO DISORDER; MASTALGIA; MONOTHERAPY; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PALLIATIVE THERAPY; PHYSICAL CAPACITY; PROCTITIS; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SWELLING; URETHRA STRICTURE; URINE INCONTINENCE; WATCHFUL WAITING; WEIGHT GAIN; CANCER STAGING; DISEASE COURSE; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; RADIOTHERAPY;

ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 69449085747     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2008.9     Document Type: Review

References (30)

1. American Joint Committee on Cancer. Prostate. AJCC Cancer Staging Manual. New York, NY: Springer; 2002. p309-16.
2. Payne H, Gillatt D. Differences and commonalities in the management of locally advanced prostate cancer: Results from a survey of oncologists and urologists in the UK. BJU Int 2007; 3: 545-53.
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, et al Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-97.
4. Rana A, Chisholm GD, Khan M, Rashwan HM, Elton RA. Conservative management with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate. Br J Urol 1994; 74: 637-41.
5. Parker MC, Cook A, Riddle PR, Fryatt I, O'Sullivan J, et al. Is delayed treatment justified in carcinoma of the prostate? Br J Urol 1985; 57: 724-8.
6. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79:235-46.
7. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24: 1868-76.
8. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, et al; Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-54.
9. Amling CL, Leibovich BC, Lerner SE, Bergstralh EJ, Blute ML, et al Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol 1997; 15: 215-21.
10. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, et al; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8.
11. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 2006; 296: 2329-35.
12. Parker C, Sydes MR, Catton C, Kynaston H, Logue J, et al; (RADICALS Trial Management Group). Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 2007; 99: 1376-9.
13. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, et al; Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-9.
14. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, et al. Radiation therapy for clinically localized prostate cancer: A multi- institutional pooled analysis. JAMA 1999; 281: 1598-604.
15. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000; 47: 609-15.
16. Zagars GK, Pollack A, Von Eschenbach AC. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 1997; 80: 764-75.
17. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999; 353: 267-72.
18. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097-105.
19. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, et al.; RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-87.
20. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166: 876-81.
21. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: What is it, really? Radiother Oncol 2005; 76: 1-3.
22. Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 2005; 62: 1322-31.
23. Henderson A, Langley SE, Laing RW. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol (R Coll Radiol) 2003; 15: 318-21.
24. Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29: 755-61.
25. Linberg R, Conover CD, Shum KL, Shorr RG. Increased tissue oxygenation and enhanced radiation sensitivity of solid tumors in rodents following polyethylene glycol conjugated bovine hemoglobin administration. In Vivo 1998; 12: 167-73.
26. Hara I, Miyake H, Yamada Y, Takechi Y, Hara S, et al. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate. Int J Urol 2002; 9: 322-8.
27. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52.
28. Bolla M, Collette L, Blank L, Warde P, Dubois JB, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360: 103-6.
29. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90.
30. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-54.